Market Cap | 4.30M | P/E | - | EPS this Y | 94.10% | Ern Qtrly Grth | - |
Income | -26.16M | Forward P/E | -0.58 | EPS next Y | 88.30% | 50D Avg Chg | -22.00% |
Sales | 9.81M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -73.00% |
Dividend | N/A | Price/Book | 0.50 | EPS next 5Y | - | 52W High Chg | -96.00% |
Recommedations | 2.00 | Quick Ratio | 0.81 | Shares Outstanding | 23.46M | 52W Low Chg | 11.00% |
Insider Own | 11.16% | ROA | -61.93% | Shares Float | 11.66M | Beta | 1.18 |
Inst Own | 1.97% | ROE | -217.75% | Shares Shorted/Prior | 428.69K/830.82K | Price | 1.46 |
Gross Margin | 54.11% | Profit Margin | -266.76% | Avg. Volume | 165,370 | Target Price | 1.00 |
Oper. Margin | -143.99% | Earnings Date | Apr 15 | Volume | 63,032 | Change | 2.82% |
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation. It also offers ReShapeCare virtual health coaching program, a program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
STANKOVICH THOMAS | Chief Financial Offi.. Chief Financial Officer | Nov 04 | Sell | 0.27 | 8,393 | 2,266 | 332,761 | 11/10/22 |
STANKOVICH THOMAS | Chief Financial Offi.. Chief Financial Officer | Aug 05 | Sell | 0.47 | 4,728 | 2,222 | 351,791 | 08/11/22 |
Bandy Barton P. | President and CEO President and CEO | Aug 05 | Sell | 0.47 | 11,674 | 5,487 | 773,098 | 08/11/22 |
Bandy Barton P. | President and CEO President and CEO | Jun 01 | Sell | 0.96 | 11,309 | 10,857 | 796,214 | 06/06/22 |
STANKOVICH THOMAS | Chief Financial Offi.. Chief Financial Officer | May 31 | Buy | 0.91 | 20,000 | 18,200 | 365,627 | 06/01/22 |
STANKOVICH THOMAS | Chief Financial Offi.. Chief Financial Officer | Apr 01 | Sell | 1.13 | 5,038 | 5,693 | 350,156 | 04/08/22 |
Bandy Barton P. | President and CEO President and CEO | Jan 04 | Sell | 1.79 | 7,150 | 12,798 | 844,865 | 01/28/22 |
STANKOVICH THOMAS | Chief Financial Offi.. Chief Financial Officer | Jan 04 | Sell | 1.78 | 3,171 | 5,644 | 362,536 | 01/28/22 |